Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies

被引:18
|
作者
Mison, L
Seed, CR
Margaritis, AR
Hyland, C
机构
[1] Australian Red Cross Blood Serv, Brisbane, Qld, Australia
[2] Australian Red Cross Blood Serv, Perth, WA, Australia
关键词
anti-HCV antibody; blood screening; NAT; seroconversion;
D O I
10.1046/j.1423-0410.2003.00246.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives The aim of this study was to compare the performance of two high-throughput strategies for hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1) RNA nucleic acid technology (NAT) screening in a volunteer blood-donor population. Materials and Methods The semiautomated Chiron Procleix HIV-1/HCV transcription mediated amplification (TMA) assay was used to screen 1 439 765 donations in two different testing configurations. Three sites (termed PDT sites) performed a mixture of individual donation (ID) and minipool (MP) testing, where 1 113 288 donations were screened as pools of 24 and an additional 32 003 donations were screened in ID format. A further two sites (termed SDT sites) screened 294 474 donations exclusively in ID format. Results A significantly higher proportion of initial NAT reactives that failed to react on follow-up testing [termed non-repeatably reactive (NRR)] was observed for ID testing at SDT sites than at PDT sites (0.082 vs. 0.047%: P < 0.01). Within the PDT sites, however, there was no significant difference between the NRR rate for MP or ID samples (0.037 vs. 0.047%; not significant). There was a significant difference in failed run rates between PDT and SDT sites (P < 0.01), with PDT sites having a higher run failure rate owing to non-amplification of the internal control. The PDT sites also had a significantly higher overall invalid sample rate. However, the invalid sample rate, specifically caused by known equipment failure, was significantly higher in the SDT sites, possibly attributable to greater usage (P < 0.0001). Four HCV NAT-positive/antibody-negative samples were identified in the course of the study. Conclusions The comparison of the performance of PDT with SDT sites identified only minor differences that did not adversely impact on the timely release of blood products. Although both ID and MP strategies showed excellent specificity, irrespective of site configuration, the significantly increased NRR rate, observed exclusively for ID testing performed at SDT sites, indicates a potential for contamination that may limit the number of samples that can optimally be processed using ID testing. The performance data for ID testing in particular should serve as a useful benchmark for evaluating candidate NAT systems that are fully automated.
引用
收藏
页码:11 / 19
页数:9
相关论文
共 50 条
  • [1] Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing
    Fang, CT
    Field, SP
    Busch, MP
    Heyns, AD
    VOX SANGUINIS, 2003, 85 (01) : 9 - 19
  • [2] Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand
    Nantachit, Niwes
    Thaikruea, Lakkana
    Thongsawat, Satawat
    Leetrakool, Nipapan
    Fongsatikul, Ladda
    Sompan, Prakai
    Fong, Yiu-Lian
    Nichols, David
    Ziermann, Rainer
    Ness, Paul
    Nelson, Kenrad E.
    TRANSFUSION, 2007, 47 (10) : 1803 - 1808
  • [3] Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations
    Bamaga, Mohammad S.
    Bokhari, Fawzi F.
    Aboud, AbdulRahaman M.
    Al-Malki, Meshal
    Alenzi, Faris Q.
    SAUDI MEDICAL JOURNAL, 2006, 27 (06) : 781 - 787
  • [4] Nucleic acid testing of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus 1, 2 in blood donors in the General University Hospital, Prague
    Duskova, D.
    Darebnicek, L.
    ACTA VIROLOGICA, 2014, 58 (02) : 146 - 151
  • [5] Use of nucleic acid testing for blood donor screening of Human Immunodeficiency virus and Hepatitis C virus in the Saudi population
    Akhter, J
    Roberts, GT
    Perry, A
    Gaucher, JS
    Howman, PA
    SAUDI MEDICAL JOURNAL, 2001, 22 (12) : 1073 - 1075
  • [6] Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA
    Margaritis, Angelo R.
    Brown, Stewart M.
    Seed, Clive R.
    Kiely, Philip
    D'Agostino, Bruno
    Keller, Anthony J.
    TRANSFUSION, 2007, 47 (10) : 1783 - 1793
  • [7] High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan
    Mine, H
    Emura, H
    Miyamoto, M
    Tomono, T
    Minegishi, K
    Murokawa, H
    Yamanaka, R
    Yoshikawa, A
    Nishioka, K
    JOURNAL OF VIROLOGICAL METHODS, 2003, 112 (1-2) : 145 - 151
  • [8] Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus-1 & hepatitis B & C viruses in Indian blood donors
    Makroo, R. N.
    Choudhury, N.
    Jagannathan, L.
    Parihar-Malhotra, M.
    Raina, V.
    Chaudhary, R. K.
    Marwaha, N.
    Bhatia, N. K.
    Ganguly, A. K.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2008, 127 (02) : 140 - 147
  • [9] Comparison of two nucleic acid amplification technology systems for detection of human immunodeficiency virus,hepatitis B virus, and hepatitis C virus
    Coleman, Charl
    Lelie, Nico
    Rademeyer, Ronel
    van Drimmelen, Harry
    van den Berg, Karin
    Vermeulen, Marion
    TRANSFUSION, 2020, 60 (12) : 2929 - 2937
  • [10] Evaluation of hepatitis C virus nucleic acid testing and HIV nucleic acid testing for blood donors
    Alabdallat, Nessrin Ghazi
    Alanazi, Hana
    Alyenbaawi, Hadeel
    Aldosari, Sahar
    Jahan, Sadaf
    ASIAN JOURNAL OF PHARMACEUTICAL RESEARCH AND HEALTH CARE, 2023, 15 (03) : 288 - 291